- Galena Biopharma and SELLAS Life Sciences have agreed to a reverse merger transaction where Galena will acquire all outstanding shares of SELLAS in exchange for newly issued Galena common stock.
- Upon completion of the proposed merger, Galena shareholders will own approximately 32.5% and SELLAS shareholders will own approximately 67.5% of the combined company.
- The combined company will focus on developing novel immunotherapies and targeted therapies for cancer and other diseases, leveraging both companies' clinical stage pipelines and expertise in immunotherapy.
Shareholder merger slides 8 dec 17 - final2Galenabio
The document proposes a merger between Galena Biopharma, Inc. and SELLAS Life Sciences Group Ltd. It provides forward-looking statements about the continuing company and risks associated with the proposed merger. It also provides details about the proposed merger such as voting by stockholders, leadership and board of the continuing company, the pipeline of clinical programs, and recent announcements. The document seeks stockholder approval of 10 proposals related to the proposed merger.
- HEXO is a Canadian cannabis company with global ambitions seeking to become a top global cannabis company.
- They have several competitive advantages including being a focused adult-use brand company, a low cost Canadian producer, having leading market share in Quebec, and being an innovation and IP leader.
- Their strategic priorities include achieving positive adjusted EBITDA by January 2021, increasing market share outside Quebec, operational excellence, product innovation, and market leadership.
This presentation provides an overview of HEXO Corp., a vertically integrated cannabis company. Some key points:
- HEXO has experienced steady revenue growth over the past year and achieved positive adjusted EBITDA in Q2 FY2021.
- The company has a number of competitive advantages including #1 market share in Quebec, partnerships with Molson Coors, and a robust IP portfolio.
- HEXO has a portfolio of brands across price points targeting various market segments. These include offerings for value-conscious, mainstream, and premium consumers.
Impax provides an overview of its growth strategy, operations, generic and branded businesses, and 2014 financial outlook. The company's growth strategy focuses on internal and external R&D opportunities, M&A, and business development to drive revenue growth. Key generic products launched in 2013 include oxymorphone ER and authorized generics of Zomig and Trilipix. The branded pipeline includes RYTARY for Parkinson's disease and a bupivacaine patch for postherpetic neuralgia. For 2014, Impax forecasts adjusted gross margins in the low 50% range and expenses of $82-88M for generic R&D and $36-39M for branded R&D.
This document provides an overview of Guyana Goldfields Inc., a gold mining company with operations in Guyana. Some key points:
- Guyana Goldfields operates the high-grade Aurora gold mine in Guyana, which has over 16 years of reserve life and exploration potential across its 200,000-acre land package.
- In 2018, production guidance was revised down to 150,000-155,000 ounces due to lower than expected head grades, and the company has engaged an independent firm to review the resource model.
- The company has a strong balance sheet with $93 million in cash and $45 million in debt as of September 2018.
- Management changes and a mill expansion are expected
Australian Business Forum helps Australian SMEs and businesses to understand the Chinese market and refine their China strategy.
http://abf.events/
ABOUT THE PRESENTATION
Presentation on Starpharma’s Polylysine Dendrimers, given by Dr. Tony Eglezos at the Fortune Forum 2015 Australian Summit.
MedReleaf is a Canadian licensed producer of medical cannabis with a market capitalization of $890 million. It has the largest market share of the Canadian medical cannabis market at 82%. The presentation discusses MedReleaf's strategy of focusing on quality, innovation, and profitability to establish itself as the standard in the medical cannabis industry. It highlights the company's expansion plans, new product development, and growth opportunities in medical cannabis in Canada and international markets.
This investor presentation by MedReleaf provides the following information in 3 sentences:
MedReleaf is a Canadian licensed producer of medical cannabis with a market share of 82% of the total Canadian medical cannabis market. They have a low-cost production model with a cash cost per gram of $1.46 and grams produced per square foot of 300. MedReleaf is pursuing an expansion strategy through increasing production capacity, developing new product lines, entering international markets, and potential opportunities in the recreational cannabis market.
Shareholder merger slides 8 dec 17 - final2Galenabio
The document proposes a merger between Galena Biopharma, Inc. and SELLAS Life Sciences Group Ltd. It provides forward-looking statements about the continuing company and risks associated with the proposed merger. It also provides details about the proposed merger such as voting by stockholders, leadership and board of the continuing company, the pipeline of clinical programs, and recent announcements. The document seeks stockholder approval of 10 proposals related to the proposed merger.
- HEXO is a Canadian cannabis company with global ambitions seeking to become a top global cannabis company.
- They have several competitive advantages including being a focused adult-use brand company, a low cost Canadian producer, having leading market share in Quebec, and being an innovation and IP leader.
- Their strategic priorities include achieving positive adjusted EBITDA by January 2021, increasing market share outside Quebec, operational excellence, product innovation, and market leadership.
This presentation provides an overview of HEXO Corp., a vertically integrated cannabis company. Some key points:
- HEXO has experienced steady revenue growth over the past year and achieved positive adjusted EBITDA in Q2 FY2021.
- The company has a number of competitive advantages including #1 market share in Quebec, partnerships with Molson Coors, and a robust IP portfolio.
- HEXO has a portfolio of brands across price points targeting various market segments. These include offerings for value-conscious, mainstream, and premium consumers.
Impax provides an overview of its growth strategy, operations, generic and branded businesses, and 2014 financial outlook. The company's growth strategy focuses on internal and external R&D opportunities, M&A, and business development to drive revenue growth. Key generic products launched in 2013 include oxymorphone ER and authorized generics of Zomig and Trilipix. The branded pipeline includes RYTARY for Parkinson's disease and a bupivacaine patch for postherpetic neuralgia. For 2014, Impax forecasts adjusted gross margins in the low 50% range and expenses of $82-88M for generic R&D and $36-39M for branded R&D.
This document provides an overview of Guyana Goldfields Inc., a gold mining company with operations in Guyana. Some key points:
- Guyana Goldfields operates the high-grade Aurora gold mine in Guyana, which has over 16 years of reserve life and exploration potential across its 200,000-acre land package.
- In 2018, production guidance was revised down to 150,000-155,000 ounces due to lower than expected head grades, and the company has engaged an independent firm to review the resource model.
- The company has a strong balance sheet with $93 million in cash and $45 million in debt as of September 2018.
- Management changes and a mill expansion are expected
Australian Business Forum helps Australian SMEs and businesses to understand the Chinese market and refine their China strategy.
http://abf.events/
ABOUT THE PRESENTATION
Presentation on Starpharma’s Polylysine Dendrimers, given by Dr. Tony Eglezos at the Fortune Forum 2015 Australian Summit.
MedReleaf is a Canadian licensed producer of medical cannabis with a market capitalization of $890 million. It has the largest market share of the Canadian medical cannabis market at 82%. The presentation discusses MedReleaf's strategy of focusing on quality, innovation, and profitability to establish itself as the standard in the medical cannabis industry. It highlights the company's expansion plans, new product development, and growth opportunities in medical cannabis in Canada and international markets.
This investor presentation by MedReleaf provides the following information in 3 sentences:
MedReleaf is a Canadian licensed producer of medical cannabis with a market share of 82% of the total Canadian medical cannabis market. They have a low-cost production model with a cash cost per gram of $1.46 and grams produced per square foot of 300. MedReleaf is pursuing an expansion strategy through increasing production capacity, developing new product lines, entering international markets, and potential opportunities in the recreational cannabis market.
Impax acquires tower holdings inc and lineage therapeutics inc oct 9 2014impax-labs
Impax to acquire Tower Holdings Inc. and Lineage Therapeutics Inc. for $700 million in cash. The acquisition adds a portfolio of growing branded and generic products that are expected to generate $215-225 million in revenue and $80-85 million in EBITDA in 2014. The deal provides strategic benefits like diversifying Impax's product portfolio and expanding its manufacturing capabilities. It is also expected to be immediately accretive to Impax's earnings per share.
Growth Stalk Holdings Corp. is a holding company focused on building a diversified cannabis portfolio through partnerships. It uses a multi-company structure to allow its divisions to benefit from vertical integration while maintaining independence. The company plans to go public through an OTC listing to access capital and valuation multiples up to 20x earnings. It has acquired companies projected to generate $2.8 million in revenue in year two.
The Shell Directional Policy Matrix (SDPM) is a refinement of the Boston Consulting Group Matrix that Shell uses to evaluate its strategic business units. The SDPM places each SBU on a grid based on the profitability prospects of its business sector on the horizontal axis and the SBU's competitive capabilities on the vertical axis. Each quadrant of the matrix indicates a different strategic recommendation, such as divesting SBUs in sectors with weak prospects and low competitive positioning, or focusing major resources on market leadership SBUs. The SDPM provides Shell a systematic framework to assess SBUs and guide strategic resource allocation decisions.
Impax Laboratories presented at the Cowen & Co Health Care Conference on March 6, 2013. They discussed their progress in improving quality operations and resolving FDA observations. They are committed to improving operations but have more work to do to fully address issues. Impax also outlined their strategy to create long-term growth through diversifying their generic product mix, building their branded neurology pipeline, and pursuing business development opportunities, supported by their strong financial position with $299 million in cash.
Cowen Co Health Care Conference March 6 2013impax-labs
Impax Laboratories is committed to improving its quality operations and resolving an FDA warning letter. It has made significant improvements over the past two years through changes to quality management and increased quality staffing. However, more work remains to be done to complete its quality improvement program and address recent FDA observations. Impax is also focused on growing its generic and branded drug pipelines to target sustainable markets. It has established competencies in complex drug development and delivery and seeks to diversify its generic portfolio and build its neurology-focused branded pipeline.
The document discusses HEXO Corp.'s strategic plan to become operationally cash flow positive within the next four quarters. Key elements of the plan include continuing to reduce manufacturing and production costs, streamlining operations, realizing synergies from acquisitions, focusing on disciplined pricing, and accelerating growth. The plan aims to leverage HEXO's assets and capabilities to improve productivity, reduce costs, exceed synergy targets from acquisitions, and improve production, demand planning, and innovation to capture missed revenue opportunities. Executing this plan is expected to generate $37.5 million in incremental cash flow in 2022 and an additional $135 million in 2023.
Second Quarter Fiscal 2019 STZ Investor Overview Presentationconstellationbrands
This document provides an overview of Constellation Brands' investment in Canopy Growth Corporation and the cannabis market opportunity. It discusses Constellation's goal of building a single global cannabis platform to address all markets and formats to succeed in this complex, rapidly evolving industry expected to grow to over $200 billion globally within 15 years. The summary highlights Constellation's view that cannabis will demonstrate similar category dynamics to total beverage alcohol, playing to its strengths.
This document is an investor presentation from Canadian Tire Corporation providing an overview of the company and its businesses. It discusses the company's strengths in areas like its iconic retail brands, market leadership positions, and real estate portfolio. It outlines growth strategies like investing in digital capabilities, private brands, and expanding retail networks. Financial highlights show growth in revenue, earnings, and same-store sales across its retail banners and continued growth at CT REIT.
Jp morgan 34th annual healthcare conferenceimpax-labs
Impax provides a cautionary statement regarding forward-looking statements in their presentation at the J.P. Morgan Healthcare Conference. They discuss key priorities for 2016 including maintaining quality and compliance across facilities, optimizing existing generic opportunities and launching up to 16 new generics, effectively utilizing an expanded specialty sales force, optimizing R&D through new product development, and pursuing value-enhancing business development opportunities including licensing for NUMIENT outside the US. Impax is well-positioned for future growth through their dual generic and specialty platforms and established core competencies.
Constellation Brands provides a 3-sentence investor overview presentation:
1) It outlines strategies to build shareholder value through profitable growth, optimizing its wine and spirits portfolio, and planned cash returns to shareholders through 2022.
2) Key highlights include expectations for Canopy Growth to achieve a $1 billion CAD revenue run rate by 2020 and for Constellation's beer business to outpace the U.S. market by a wide margin.
3) The presentation also reviews evolving consumer trends in beer, wine, and spirits and Constellation's strategies to win with consumers through powerful brands, innovation, premiumization focus, and understanding demographics.
shire-to-acquire-dyax-presentation-final-02-nov-2015Aaron Sato
Shire will acquire Dyax Corp. to expand its leadership position in treating rare diseases like hereditary angioedema (HAE). Dyax's Phase 3-ready therapy, DX-2930, is a long-acting injectable drug for HAE prophylaxis that could generate $2 billion in annual sales if approved. The acquisition enhances Shire's growth by adding an innovative late-stage asset with potential for greater efficacy and more convenient dosing than current HAE treatments. The transaction delivers substantial value for shareholders of both companies by expanding Shire's HAE franchise and rare disease pipeline.
Hofers Method Of Business Portfolio Analysis[1].Ppt2003k16
Business portfolio analysis is a technique used to develop corporate strategy by analyzing a company's collection of businesses and products similarly to how financial investments are analyzed. It involves analyzing the strengths and opportunities for a company's portfolio. Key matrices used include the BCG Growth-Share Matrix, GE Multifactor Portfolio Matrix, and Matsushita Strategy Matrix. Analyzing financial trends, competitive position, and market evolution help determine strategic choices for businesses. The Product/Market Evolution Portfolio Matrix developed by Hofer and Schendel plots businesses based on competitive position and industry life cycle stage to better identify developing winners.
Jefferies Global Healthcare Conference June 5 2013impax-labs
This document contains a "Safe Harbor" statement regarding forward-looking statements in the presentation. It notes several risks and uncertainties that could cause the company's future results to differ from forward-looking statements, including economic conditions, issues raised by the FDA in warning letters and observations, developing and commercializing pharmaceutical products, reductions in business with significant customers, the impact of competition, and other regulatory, legal and operational risks. It also provides an overview of the company's generic and branded product pipelines and growth strategies focusing on organic growth, partnerships, and M&A.
Forage Hyperfoods produces functional mushroom products and is seeking investor funding. It currently generates revenue through wholesale customers for raw and extracted mushrooms. Forage aims to expand production capacity and inventory to meet increased demand as the functional food market grows. Key milestones for 2021 include launching new product lines, establishing operations in the Caribbean, and formalizing large distribution agreements. Proceeds from funding will be used for operations, sales, increasing inventory, and product expansion. Forage sees potential for significant revenue and market share growth in the functional food and mushroom supplement industries.
This presentation provides an overview of HEXO Corp., a vertically integrated cannabis company. Some key points:
- HEXO has experienced steady revenue growth quarter-over-quarter and achieved positive adjusted EBITDA in Q2 FY2021.
- The company has a number of competitive advantages including a #1 market share position in Quebec, a partnership with Molson Coors for cannabis beverages, and a robust portfolio of cannabis patents.
- HEXO has established several leading brands like Truss Beverages and Original Stash that have achieved strong sales metrics and market share in various provinces.
- Canadian Tire Corporation holds an investor presentation outlining its various retail banners including Canadian Tire, FGL Sports, Mark's, and CT REIT.
- It provides an overview of the strengths and growth strategies for each banner, emphasizing digital innovation, exclusive products, and community engagement.
- Financial highlights for 2015 show overall revenue of $12.3 billion with Canadian Tire representing over half at $6.4 billion and growth across most banners.
Bank of America Merrill Lynch Healthcare ConferenceImpaxLaboratories
- The document is a presentation by Impax Laboratories at a health care conference discussing its business strategies and outlook.
- Impax has two platforms for growth - generics targeting $25B in US sales and brands focused on central nervous system drugs.
- Its strategies include organic growth of its generic and brand pipelines, strategic partnerships mainly for alternative dosage forms, and mergers and acquisitions mainly for alternative dosage forms.
Bank of America Merrill Lynch Health Care Conferene May 16 2013impax-labs
- The document is a presentation by Impax Laboratories at a health care conference discussing its business strategies and outlook.
- Impax has two platforms for growth - generics targeting $25B in US sales and brands focused on central nervous system drugs.
- Its strategies include organic growth of its generic and brand pipelines, strategic partnerships mainly in alternative dosage forms, and mergers and acquisitions mainly in alternative dosage forms.
Impax Laboratories Credit Suisse 2013 Healthcare Conference November 14, 2013impax-labs
1) The document contains a "Safe Harbor Statement" noting that statements in the presentation contain forward-looking information and are subject to risks and uncertainties.
2) It discusses Impax Laboratories' positioning for future growth through its generic and branded platforms, established core competencies, and strong financial profile.
3) It provides an overview of Impax's two growth platforms - generics and brands, noting key areas of focus and pipeline products for each.
1) The company has a diversified pipeline including hematology and immunotherapy programs with multiple clinical trials in mid to late stages.
2) Their lead hematology candidate, GALE-401, is a controlled release formulation of anagrelide for the treatment of essential thrombocythemia that has demonstrated an improved safety profile over immediate release formulations in clinical trials to date.
3) Their immunotherapy programs include NeuVax for HER2-positive breast cancer, which has shown strong CD8+ T-cell responses in clinical trials both as a single agent and in combination with trastuzumab.
A hematology and oncology focused company has a diversified pipeline with multiple mid-to-late stage clinical trials. Their lead program is GALE-401 for essential thrombocythemia, which is a controlled release formulation of anagrelide in Phase 3 ready. Their immunotherapy programs include NeuVax for HER2-positive breast cancer in multiple Phase 2 trials in combination with Herceptin, and GALE-301/302 targeting folate binding protein in early stage trials.
More Related Content
Similar to Sellas galena merger slides 8 aug 17- final
Impax acquires tower holdings inc and lineage therapeutics inc oct 9 2014impax-labs
Impax to acquire Tower Holdings Inc. and Lineage Therapeutics Inc. for $700 million in cash. The acquisition adds a portfolio of growing branded and generic products that are expected to generate $215-225 million in revenue and $80-85 million in EBITDA in 2014. The deal provides strategic benefits like diversifying Impax's product portfolio and expanding its manufacturing capabilities. It is also expected to be immediately accretive to Impax's earnings per share.
Growth Stalk Holdings Corp. is a holding company focused on building a diversified cannabis portfolio through partnerships. It uses a multi-company structure to allow its divisions to benefit from vertical integration while maintaining independence. The company plans to go public through an OTC listing to access capital and valuation multiples up to 20x earnings. It has acquired companies projected to generate $2.8 million in revenue in year two.
The Shell Directional Policy Matrix (SDPM) is a refinement of the Boston Consulting Group Matrix that Shell uses to evaluate its strategic business units. The SDPM places each SBU on a grid based on the profitability prospects of its business sector on the horizontal axis and the SBU's competitive capabilities on the vertical axis. Each quadrant of the matrix indicates a different strategic recommendation, such as divesting SBUs in sectors with weak prospects and low competitive positioning, or focusing major resources on market leadership SBUs. The SDPM provides Shell a systematic framework to assess SBUs and guide strategic resource allocation decisions.
Impax Laboratories presented at the Cowen & Co Health Care Conference on March 6, 2013. They discussed their progress in improving quality operations and resolving FDA observations. They are committed to improving operations but have more work to do to fully address issues. Impax also outlined their strategy to create long-term growth through diversifying their generic product mix, building their branded neurology pipeline, and pursuing business development opportunities, supported by their strong financial position with $299 million in cash.
Cowen Co Health Care Conference March 6 2013impax-labs
Impax Laboratories is committed to improving its quality operations and resolving an FDA warning letter. It has made significant improvements over the past two years through changes to quality management and increased quality staffing. However, more work remains to be done to complete its quality improvement program and address recent FDA observations. Impax is also focused on growing its generic and branded drug pipelines to target sustainable markets. It has established competencies in complex drug development and delivery and seeks to diversify its generic portfolio and build its neurology-focused branded pipeline.
The document discusses HEXO Corp.'s strategic plan to become operationally cash flow positive within the next four quarters. Key elements of the plan include continuing to reduce manufacturing and production costs, streamlining operations, realizing synergies from acquisitions, focusing on disciplined pricing, and accelerating growth. The plan aims to leverage HEXO's assets and capabilities to improve productivity, reduce costs, exceed synergy targets from acquisitions, and improve production, demand planning, and innovation to capture missed revenue opportunities. Executing this plan is expected to generate $37.5 million in incremental cash flow in 2022 and an additional $135 million in 2023.
Second Quarter Fiscal 2019 STZ Investor Overview Presentationconstellationbrands
This document provides an overview of Constellation Brands' investment in Canopy Growth Corporation and the cannabis market opportunity. It discusses Constellation's goal of building a single global cannabis platform to address all markets and formats to succeed in this complex, rapidly evolving industry expected to grow to over $200 billion globally within 15 years. The summary highlights Constellation's view that cannabis will demonstrate similar category dynamics to total beverage alcohol, playing to its strengths.
This document is an investor presentation from Canadian Tire Corporation providing an overview of the company and its businesses. It discusses the company's strengths in areas like its iconic retail brands, market leadership positions, and real estate portfolio. It outlines growth strategies like investing in digital capabilities, private brands, and expanding retail networks. Financial highlights show growth in revenue, earnings, and same-store sales across its retail banners and continued growth at CT REIT.
Jp morgan 34th annual healthcare conferenceimpax-labs
Impax provides a cautionary statement regarding forward-looking statements in their presentation at the J.P. Morgan Healthcare Conference. They discuss key priorities for 2016 including maintaining quality and compliance across facilities, optimizing existing generic opportunities and launching up to 16 new generics, effectively utilizing an expanded specialty sales force, optimizing R&D through new product development, and pursuing value-enhancing business development opportunities including licensing for NUMIENT outside the US. Impax is well-positioned for future growth through their dual generic and specialty platforms and established core competencies.
Constellation Brands provides a 3-sentence investor overview presentation:
1) It outlines strategies to build shareholder value through profitable growth, optimizing its wine and spirits portfolio, and planned cash returns to shareholders through 2022.
2) Key highlights include expectations for Canopy Growth to achieve a $1 billion CAD revenue run rate by 2020 and for Constellation's beer business to outpace the U.S. market by a wide margin.
3) The presentation also reviews evolving consumer trends in beer, wine, and spirits and Constellation's strategies to win with consumers through powerful brands, innovation, premiumization focus, and understanding demographics.
shire-to-acquire-dyax-presentation-final-02-nov-2015Aaron Sato
Shire will acquire Dyax Corp. to expand its leadership position in treating rare diseases like hereditary angioedema (HAE). Dyax's Phase 3-ready therapy, DX-2930, is a long-acting injectable drug for HAE prophylaxis that could generate $2 billion in annual sales if approved. The acquisition enhances Shire's growth by adding an innovative late-stage asset with potential for greater efficacy and more convenient dosing than current HAE treatments. The transaction delivers substantial value for shareholders of both companies by expanding Shire's HAE franchise and rare disease pipeline.
Hofers Method Of Business Portfolio Analysis[1].Ppt2003k16
Business portfolio analysis is a technique used to develop corporate strategy by analyzing a company's collection of businesses and products similarly to how financial investments are analyzed. It involves analyzing the strengths and opportunities for a company's portfolio. Key matrices used include the BCG Growth-Share Matrix, GE Multifactor Portfolio Matrix, and Matsushita Strategy Matrix. Analyzing financial trends, competitive position, and market evolution help determine strategic choices for businesses. The Product/Market Evolution Portfolio Matrix developed by Hofer and Schendel plots businesses based on competitive position and industry life cycle stage to better identify developing winners.
Jefferies Global Healthcare Conference June 5 2013impax-labs
This document contains a "Safe Harbor" statement regarding forward-looking statements in the presentation. It notes several risks and uncertainties that could cause the company's future results to differ from forward-looking statements, including economic conditions, issues raised by the FDA in warning letters and observations, developing and commercializing pharmaceutical products, reductions in business with significant customers, the impact of competition, and other regulatory, legal and operational risks. It also provides an overview of the company's generic and branded product pipelines and growth strategies focusing on organic growth, partnerships, and M&A.
Forage Hyperfoods produces functional mushroom products and is seeking investor funding. It currently generates revenue through wholesale customers for raw and extracted mushrooms. Forage aims to expand production capacity and inventory to meet increased demand as the functional food market grows. Key milestones for 2021 include launching new product lines, establishing operations in the Caribbean, and formalizing large distribution agreements. Proceeds from funding will be used for operations, sales, increasing inventory, and product expansion. Forage sees potential for significant revenue and market share growth in the functional food and mushroom supplement industries.
This presentation provides an overview of HEXO Corp., a vertically integrated cannabis company. Some key points:
- HEXO has experienced steady revenue growth quarter-over-quarter and achieved positive adjusted EBITDA in Q2 FY2021.
- The company has a number of competitive advantages including a #1 market share position in Quebec, a partnership with Molson Coors for cannabis beverages, and a robust portfolio of cannabis patents.
- HEXO has established several leading brands like Truss Beverages and Original Stash that have achieved strong sales metrics and market share in various provinces.
- Canadian Tire Corporation holds an investor presentation outlining its various retail banners including Canadian Tire, FGL Sports, Mark's, and CT REIT.
- It provides an overview of the strengths and growth strategies for each banner, emphasizing digital innovation, exclusive products, and community engagement.
- Financial highlights for 2015 show overall revenue of $12.3 billion with Canadian Tire representing over half at $6.4 billion and growth across most banners.
Bank of America Merrill Lynch Healthcare ConferenceImpaxLaboratories
- The document is a presentation by Impax Laboratories at a health care conference discussing its business strategies and outlook.
- Impax has two platforms for growth - generics targeting $25B in US sales and brands focused on central nervous system drugs.
- Its strategies include organic growth of its generic and brand pipelines, strategic partnerships mainly for alternative dosage forms, and mergers and acquisitions mainly for alternative dosage forms.
Bank of America Merrill Lynch Health Care Conferene May 16 2013impax-labs
- The document is a presentation by Impax Laboratories at a health care conference discussing its business strategies and outlook.
- Impax has two platforms for growth - generics targeting $25B in US sales and brands focused on central nervous system drugs.
- Its strategies include organic growth of its generic and brand pipelines, strategic partnerships mainly in alternative dosage forms, and mergers and acquisitions mainly in alternative dosage forms.
Impax Laboratories Credit Suisse 2013 Healthcare Conference November 14, 2013impax-labs
1) The document contains a "Safe Harbor Statement" noting that statements in the presentation contain forward-looking information and are subject to risks and uncertainties.
2) It discusses Impax Laboratories' positioning for future growth through its generic and branded platforms, established core competencies, and strong financial profile.
3) It provides an overview of Impax's two growth platforms - generics and brands, noting key areas of focus and pipeline products for each.
Similar to Sellas galena merger slides 8 aug 17- final (20)
1) The company has a diversified pipeline including hematology and immunotherapy programs with multiple clinical trials in mid to late stages.
2) Their lead hematology candidate, GALE-401, is a controlled release formulation of anagrelide for the treatment of essential thrombocythemia that has demonstrated an improved safety profile over immediate release formulations in clinical trials to date.
3) Their immunotherapy programs include NeuVax for HER2-positive breast cancer, which has shown strong CD8+ T-cell responses in clinical trials both as a single agent and in combination with trastuzumab.
A hematology and oncology focused company has a diversified pipeline with multiple mid-to-late stage clinical trials. Their lead program is GALE-401 for essential thrombocythemia, which is a controlled release formulation of anagrelide in Phase 3 ready. Their immunotherapy programs include NeuVax for HER2-positive breast cancer in multiple Phase 2 trials in combination with Herceptin, and GALE-301/302 targeting folate binding protein in early stage trials.
GALE-401 is a proprietary controlled release formulation of anagrelide being developed for the treatment of essential thrombocythemia (ET). Phase 1 and 2 trials show it has a favorable safety profile compared to immediate release anagrelide with fewer adverse events. A pivotal Phase 3 trial is planned for Q2 to initiate comparing GALE-401 to best available therapies in patients who failed or were intolerant to hydroxyurea.
NeuVax is an investigational immunotherapy targeting HER2-positive breast cancer. It contains an immunodominant HER2 peptide that stimulates CD8+ T-cells to destroy tumor cells. Phase 2 trials are ongoing in various breast cancer populations in combination with Hercept
GALE-401 is a controlled release formulation of anagrelide being developed for the treatment of essential thrombocythemia. Phase 1 and 2 trials show it has an improved tolerability and safety profile compared to immediate release anagrelide, with a faster onset of platelet lowering effect. The company plans to initiate a pivotal Phase 3 trial in 2017 to evaluate GALE-401's ability to reduce platelet counts in essential thrombocythemia patients. NeuVax is an immunotherapy targeting HER2-positive breast cancer that elicits a strong CD8+ T-cell immune response. It is being evaluated in multiple clinical trials in various breast and gastric cancer settings both as a monotherapy and in combination with other agents like tra
This document provides a summary of Galena Biopharma's Q3 2016 financial results and corporate update. It discusses interim results from the Phase 3 PRESENT trial of NeuVax showing a potential delay in disease-free survival and highlights the risk of pseudoprogression in cancer immunotherapy trials. It also reviews the company's immunotherapy development pipeline, including NeuVax programs in breast and gastric cancer and GALE-301/302 programs in ovarian and breast cancer. Finally, it discusses the company's cash position and expected milestones for the remainder of 2016.
GALE-401 is a proprietary controlled release formulation of anagrelide being developed for the treatment of essential thrombocythemia (ET) as a potential third line therapy. Phase 1 and 2 clinical trials showed that GALE-401 maintains platelet lowering effects while reducing peak plasma concentrations and adverse events compared to immediate release anagrelide. The company plans to initiate a Phase 3 trial in Q2 2017 to further evaluate GALE-401 in ET patients who are intolerant or refractory to first and second line therapies such as hydroxyurea and anagrelide.
GALE-401 is a controlled release formulation of anagrelide targeting patients who are intolerant to immediate release anagrelide, the current standard of care for third line treatment of essential thrombocythemia. Phase 1 and 2 clinical trials demonstrated GALE-401's improved pharmacokinetic profile with lower Cmax and longer half-life, maintaining platelet lowering effects while showing better tolerability. A Phase 3 trial is planned to initiate in Q2 2017. NeuVax is an immunotherapy targeting HER2-expressing cancers by eliciting a CD8+ T-cell immune response. Current clinical trials are investigating NeuVax in combination with trastuzumab for the treatment of HER2 1+/2+ breast cancer
This document provides Galena's Q2 2016 financial results and corporate update. It discusses Galena's product pipeline including GALE-401 for essential thrombocythemia, NeuVax for breast cancer and gastric cancer, and GALE-301/302 for ovarian and breast cancer. For GALE-401, it outlines positive preliminary results from a Phase 2 trial and plans for a Phase 2/3 trial. For NeuVax, it describes ongoing Phase 2 trials in breast cancer. For GALE-301/302, it discusses a Phase 1/2a trial showing preliminary efficacy for GALE-301. The document also provides Galena's Q2 2016 financial results and cash position.
This document provides Galena's Q2 2016 financial results and corporate update. It discusses Galena's product pipeline including GALE-401 for essential thrombocythemia, NeuVax for breast cancer and gastric cancer, and GALE-301/302 for ovarian and breast cancer. For GALE-401, it outlines positive preliminary results from a Phase 2 trial and plans for a Phase 2/3 trial. For NeuVax, it describes ongoing Phase 2 trials in breast cancer. For GALE-301/302, it discusses a Phase 1/2a trial showing preliminary efficacy for GALE-301. The document also provides Galena's Q2 2016 financial results and cash position.
The document summarizes the 2016 annual meeting of stockholders held on July 14, 2016. It includes a forward-looking statement noting risks and uncertainties in projections. The development pipeline outlines several investigational products in various phases of clinical trials for breast cancer, gastric cancer, gynecological cancers, and hematological conditions. An overview of the current status of NeuVax clinical trials in breast cancer is provided, along with collaborations. Summaries are also given for GALE-301 and GALE-401 clinical programs, corporate details, leadership, and motivation.
This presentation provides an overview of an oncology-focused immunotherapy company. It discusses the company's lead product, NeuVax, which is an immunotherapy targeting HER2-positive breast cancer in both the adjuvant and metastatic settings. Key information includes:
- NeuVax is currently in a Phase 3 clinical trial (PRESENT) in the adjuvant setting for HER2 1+/2+ breast cancer patients. Enrollment is complete for the trial.
- An interim analysis of the PRESENT trial is expected in late Q2 2016 which will evaluate safety and futility based on 70 recurrence events.
- Additional clinical trials are exploring NeuVax in combination with Herceptin and in other HER2-positive cancers like
This presentation provides an overview of an oncology-focused immunotherapy company. It discusses the company's lead product, NeuVax, which is an immunotherapy targeting HER2-positive breast cancer currently in a Phase 3 clinical trial. The presentation summarizes the clinical development pipeline, mechanism of action involving T-cell activation, positive safety profile established in previous trials, and potential commercial opportunities. It also briefly discusses the company's pipeline of products targeting other cancers, including GALE-301 and GALE-302 which target Folate Binding Protein in ovarian and endometrial cancers.
This presentation provides an overview of an oncology-focused immunotherapy company. It discusses the company's lead product, NeuVax, which is an immunotherapy targeting HER2-positive breast cancer in both the adjuvant and metastatic settings. Key information includes:
- NeuVax is currently in a Phase 3 clinical trial (PRESENT) in the adjuvant setting for HER2 1+/2+ breast cancer to prevent disease recurrence.
- Additional trials are planned or ongoing to study NeuVax in combination with Herceptin and in other HER2-positive cancers like gastric cancer.
- NeuVax works by stimulating cytotoxic T-cells to seek out and destroy tumor cells expressing HER2 and has shown a good safety profile
This presentation provides an overview of an oncology-focused immunotherapy company. It discusses the company's lead product, NeuVax, which is an immunotherapy targeting HER2-positive breast cancer in both the adjuvant and metastatic settings. Key information includes:
- NeuVax is currently in a Phase 3 clinical trial (PRESENT) in the adjuvant setting for HER2 1+/2+ breast cancer patients. Enrollment is complete for the trial.
- An interim analysis of the PRESENT trial is expected in late Q2 2016 which will evaluate safety and futility based on 70 recurrence events.
- Additional clinical trials are exploring NeuVax in combination with Herceptin and in other HER2-positive cancers like
An oncology-focused immunotherapy company is conducting a Phase 3 clinical trial of its lead product, NeuVax, for the prevention of breast cancer recurrence in early-stage, node-positive patients. The trial is fully enrolled with 758 participants and is evaluating NeuVax compared to placebo on disease-free survival. NeuVax targets the HER2 protein and consists of an HLA-A2/A3-restricted peptide that elicits CD8+ T-cell responses. Previous clinical trials demonstrated NeuVax has a positive safety profile and signals of efficacy in reducing recurrence rates. An interim analysis is upcoming in mid-2016, with final results expected in 2018.
This presentation summarizes an oncology focused immunotherapy company. Key points include:
- The company has a pioneering immunotherapy technology that induces, activates and causes proliferation of cytotoxic T-cells to target cancer.
- Clinical development is focused on secondary prevention in cancer survivors to redefine the standard of care with targeted therapies to prevent cancer recurrence.
- The company has two lead programs - NeuVax targeting HER2 positive breast and gastric cancers, and GALE-301/302 targeting folate binding protein in ovarian and endometrial cancers.
- NeuVax is in a Phase 3 clinical trial (PRESENT) in breast cancer and other trials are ongoing or planned in breast and gastric cancers. GALE-
This oncology-focused immunotherapy company is developing first-in-class peptide vaccines targeting HER2 and Folate Binding Protein (FBP) for the secondary prevention of breast, gastric, and gynecological cancers. They have an ongoing Phase 3 trial called PRESENT evaluating their lead candidate, NeuVax, in HER2-positive breast cancer patients. The company also has Phase 1/2 trials ongoing for GALE-301 targeting FBP in ovarian and endometrial cancer patients. If successful, these vaccines could redefine standard of care and improve long-term survivorship for cancer patients.
This oncology-focused immunotherapy company is developing first-in-class, targeted immunotherapies for cancer prevention. Their lead product NeuVax targets HER2-positive breast cancer in ongoing phase 3 trials. If successful, NeuVax could redefine standard of care for the majority of breast cancer patients who have low or intermediate HER2 expression. The company is also developing GALE-301, a vaccine targeting Folate Binding Protein for ovarian and endometrial cancers, which has shown preliminary efficacy in reducing recurrence rates in phase 1/2a trials.
6. • Late-stage cancer immunotherapy pipeline
• Galinpepimut-S:
• Innova;ve proper;es that differen;ate it from other products in this class
• Two Phase 3 ready indica;ons with favorable safety and compelling efficacy (overall survival)
profiles from completed Phase 2 trials
• Overall survival in Phase 2 AML trial was meaningfully longer than predicted
• Phase 3 AML trial design has been reviewed by FDA
• Phase 3 mesothelioma trial design also reviewed by FDA
• EMA & FDA Orphan Drug Designa;on and FDA Fast Track status for both se^ngs
• Ongoing Phase 2 trial in mul;ple myeloma, and a nivolumab (OPDIVO®) combina;on trial in
ovarian cancer
• Expansion of checkpoint combina;on in hematology and solid tumors planned
• NeuVax
• Mul;ple Phase 2 ISTs ongoing in breast cancer
• Phase 2b interim efficacy analysis expected in Q1 2018
• CombinaYon trials ongoing with both agents with addiYonal trials planned
• Expansion pipeline provides mulYple partnering/strategic opportuniYes
• MulYple important catalysts throughout 2018 and 2019
6
GALENA/SELLAS SYNERGISTIC DEVELOPMENT PROGRAMS
OPDIVO® is a trademark of Bristol-Myers Squibb Company.
7. LEADERSHIP TEAM
Name POSITION PRIOR EXPERIENCE / AFFILIATIONS
Angelos M. Stergiou, MD, ScD h.c. Chief Execu;ve Officer Paion AG, Biovest Interna;onal, Accen;a, Analy;ca, Avanex Life Sciences
Nicholas J. Sarlis, MD, PhD, FACP Chief Medical Officer NIH, MD Anderson, Sanofi, Incyte
William Pollei, ACA, CFA Chief Financial Officer PWC, ACE, Montpelier, Blue Capital
Gregory M. Torre, PhD, JD
Chief Regulatory Officer, &
SVP Technical Opera;ons Pfizer, Accen;a, Bristol-Meyers, Sanofi
MarYn G. Baum Chief Opera;ng Officer VestIQ, Accen;a, SkyePharma, GSK
David Moser, JD VP, Corporate Legal Affairs Accen;a, Biovest Interna;onal
7
PLANNED BOARD OF DIRECTORS
• Angelos Stergiou, MD, ScD h.c., SELLAS CEO
• Representa;ve from SELLAS
• Representa;ve from SELLAS
• New, Independent Director appointed by SELLAS
• New, Independent Director appointed by SELLAS
• New appointment by Galena
• New appointment by Galena